Hinge Health Q3 revenue jumps 52%, beats estimates
Overview
US digital health platform's Q3 revenue rose 52% yr/yr, beating analyst expectations
Adjusted EPS for Q3 more than doubled from a year ago
Company raised full-year 2026 revenue guidance, now sees 50% yr/yr growth at midpoint
Outlook
Hinge Health sees Q4 revenue between $249 mln and $251 mln
Company expects Q4 non-GAAP income from operations of $81 mln to $83 mln
Hinge Health raises 2026 revenue guidance to $879 mln-$881 mln
Result Drivers
MARGIN EXPANSION - Co reported higher gross margins yr/yr, reflecting improved operational efficiency
BILLINGS GROWTH - Last 12 months calculated billings rose 54% yr/yr, supporting revenue growth
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $234.97 mln | $224.56 mln (15 Analysts) |
Q3 Net Income | $57.40 mln | ||
Q3 Gross Profit | $204.33 mln | ||
Q3 Income from Operations | $50.33 mln | ||
Q3 Pretax Profit | $53.72 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Hinge Health, Inc. is $111.00, about 2.9% below its October 30 closing price of $114.32
Reuters Recommended Reads
Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance
Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits
Nov 2 - Anthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)